Key points are not available for this paper at this time.
Abstract Objective: Sijunzi Decoction (SJZD) is a kind of traditional Chinese medicine (TCM) formula,which has the contribution to anti-atherosclerosis.This study aims to explore the potential mechanism of the treatment of atherosclerosis (AS) with SJZD. Methods: Comprehensive analysis with transcriptomics and network pharmacology,combining with in vivo experiment and therapeutic targets. Results: Through the in vivo experiment,it was found that SJZD could significantly improve the blood lipid level and lipid deposition in ApoE−/− mice.Furthermore,4 biological processes(lipid localization,specific granule,positive regulation of lipid localization,positive regulation of lipid transport),7 targets (SPP1,EGF,OLR1,LDLR,PON1,SLP1,PLAU), and 6 active ingredients(including beta-sitosterol,kaempferol,quercetin,stigmasterol, naringenin and isorhamnetin) play an extremely important role in the treatment of AS with SJZD.We also found that the genes of OLR,SPP1 and EGF were involved in regulating oxidative stress during the progress of atherosclerosis and the improvement of endothelial dysfunction.Furthermore,SJZD could interfere the expression of mRNA and protein of OLR1,SPP1 and EGF,and respectively reduce and increase the density level of MDA and SOD in serum significantly. Conclusion:Inhibiting excessively oxidative stress and improving endothelial dysfunction by regulating OLR1/SPP1/EGF pathway could be the mechanism,by which Sijunzi decoction resists AS.
Chen et al. (Tue,) studied this question.